PROJECT

- Incontinence Associated Dermatitis (IAD) is defined as "an inflammation of the skin that occurs when urine or stool encounters the perineal or peri-genital skin (Mcnicol, Ayello, Phearman, Pezzekka, & Culver, 2018) According to Center for Medicare and Medicaid Services (2020), there is a 5.7% incidence of IAD in long term care facilities
- According to Mcnicol, Ayello, Phearman, Pezzekka, & Culver, (2018), 47% of patient within the hospital are incontinent and of that number of patients, 46% of patients develop IAD
- There is an external urinary management system designed to help manage urinary incontinence in female patients. It is composed of a silicone adhesive pad that keeps the device in place, an ultra-soft wicking fabric that absorbs and diverts urine away from skin, a Flex-Fit Core that contours to the patient's anatomy, and a tapered plastic end cap that gently sits in perineal area to secure device in position and creates a seal for suction.

2

PRE-DATA

Oct 2019 through Feb 2020

- 1. # of patients that were incontinent: 25
- # of patients that were incontinent that developed IAD: 19
- 3. % of incontinent patients developed IAD: 76%

Average Per Month (derived from data above)

- 1. # of patients that were incontinent: 5
- # of patients that were incontinent that developed IAD: 3.8
- 3. % of incontinent patients developed IAD: 76%

INTERVENTIONS

- Identify female patients in ICU who are incontinent Determine if patients are ambulatory - if not, select
- for the external urinary incontinence device
- Apply the external urinary incontinence device
- and monitor patient twice per shift to make sure IAD doesn't develop

LITERATURE SUPPORT

- Gray, M. (2010). Optimal Management of Incontinence-Associated Dermatitis in the Elderly. Am J Clin Dermatol 11, 201-210
- Beeson, T., Davis, T. (2018) Carmen Urinary Management with an External Female Collection Device, Journal of Wound, Ostomy and Continence Nursing. 45 (2), p. 187-189

The Use of an External Urinary Incontinence Device to Prevent Incontinence Associated

Dermatitis (IAD)

MEASUREMENT POINTS

Date	Score	Date	Score
July 2020	 # of patients that were incontinent: 5 # of patients that were incontinent that developed IAD: 0 % of incontinent patients developed IAD: 0% 	Aug 2020	 # of patients that were incontinent: 6 # of patients that were incontinent that developed IAD: 0 % of incontinent patients developed IAD: 0%
Sep 2020	 # of patients that were incontinent: 4 # of patients that were incontinent that developed IAD: 0 % of incontinent patients developed IAD: 0% 	Oct 2020	 # of patients that were incontinent: 3 # of patients that were incontinent that developed IAD: 0 % of incontinent patients developed IAD: 0%
Nov 2020	 # of patients that were incontinent: 3 # of patients that were incontinent that developed IAD: 0 % of incontinent patients developed IAD: 0% 		

Comparison of Incontinent Patients that Developed IAD Before & After External Urinary Incontinence Device Implementation 30.00 25.00 25.00 21.00 19.00 20.00 Incontinent Patients 15.00 Developed IAD 10.00 Linear (Developed IAD) 5.00 0.00 0.00 October 2019 through July 2020 through

November 2020

February 2020

Wound Care (Skin Champions)

CCC Team Members



IMPLEMENTATION DATE JULY 1st 2020

CONCLUSION & NEXT STEPS

- Based on the data, female patients that are incontinent and immobile greatly benefit from the use of this external incontinence management system to prevent incontinence associated dermatitis
- The next step is to implement this device in the medical surgical units for applicable patients